Previous 10 | Next 10 |
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the pricing of an underwritten public offering of 4,642,857 shares of its common stock at a price to the public o...
In recent years, promising start-ups have faced almost no obstacles to raising capital, so long as they pursued growth at all costs. Investors accepted significant losses in the present on the premise that these would translate to incredible market share in the future. The environment of easy mo...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has received ISO 27001:2013 certification for its Information Security Management System (ISMS). ISO 27001...
A trial to resolve Agilent 's (NYSE: A) dispute with biotech company Twist Biosciences (NASDAQ: TWST) won't begin on Feb. 24 after all. Instead, Twist is paying $22.5 million to settle -- without admission of wrongdoing -- litigation alleging breach of contract, breach of duty of l...
Twist Bioscience Corp (TWST) Q1 2020 Earnings Conference Call February 06, 2020, 16:30 ET Company Participants James Thorburn - CFO Emily Leproust - Co-Founder, President, CEO & Director Mark Daniels - SVP, Chief Legal Officer, Chief Ethics & Compliance Officer and Secret...
Image source: The Motley Fool. Twist Bioscience Corp (NASDAQ: TWST) Q1 2020 Earnings Call Feb 6, 2020 , 4:30 p.m. ET Operator Continue reading
The following slide deck was published by Twist Bioscience Corporation in conjunction with their 2020 Q1 earnings Read more ...
Twist Bioscience (NASDAQ: TWST ): Q1 Non-GAAP EPS of -$1.00 misses by $0.17 ; GAAP EPS of -$1.69 misses by $0.86 . More news on: Twist Bioscience Corporation, Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
-- First Quarter Fiscal 2020 Revenues of $17.2M; Increase of 49% over First Quarter Fiscal 2019 – -- Reaches Settlement Agreement with Agilent in Litigation -- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-qual...
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced it has reached a settlement agreement with Agilent Technologies to resolve all claims and counterclaims in the tr...
News, Short Squeeze, Breakout and More Instantly...
Twist Bioscience Corporation Company Name:
TWST Stock Symbol:
NASDAQ Market:
Twist Bioscience Corporation Website:
Pure Biologics’ exploratory Phase 0 study to evaluate pharmacodynamic activity of PBA-0405 in solid tumors Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today a...
Company to host conference call at 8:00 AM ET Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2024 th...
Express Genes enable faster turnaround times Twist Express Antibodies, CHO starting at 13 business days Twist Express Antibodies, HEK293 starting at 10 business days Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of ...